Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.105
Sell
RSI(14)
41.327
Neutral
STOCH(KDJ)(9,3,3)
39.447
Neutral
ATR(14)
1.016
Low Volatility
CCI(14)
-80.712
Neutral
Williams %R
76.773
Sell
TRIX(12,20)
-0.169
Sell
StochRSI(14)
32.694
Sell
Sanofi SA
SNY46.580USD
+0.380+0.82%
Market hours （ET）Quotes delayed by 15 min
113.38BMarket Cap
11.27P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sanofi SA
Currency: USD Updated: 2026-01-29Key Insights
Sanofi SA's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 57 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 59.64.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanofi SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sanofi SA Highlights
StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 11.18, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 240.38M shares, decreasing 9.29% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 34.20K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
59.643
Target Price
+25.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-29The current financial score of Sanofi SA is 8.60, ranking 53 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.39B, representing a year-over-year decrease of 1.03%, while its net profit experienced a year-over-year decrease of 5.89%.
Score
Financials
6.74
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.63
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.66
Sanofi SA's Company Valuation
Currency: USD Updated: 2026-01-29The current valuation score of Sanofi SA is 5.82, ranking 140 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 11.18, which is 187.28% below the recent high of 32.11 and 1.00% above the recent low of 11.07.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 57/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-29The current earnings forecast score of Sanofi SA is 8.40, ranking 39 out of 159 in the Pharmaceuticals industry. The average price target is 58.58, with a high of 74.67 and a low of 56.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
59.643
Target Price
+25.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Sanofi SA
SNY
10
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-29The current price momentum score of Sanofi SA is 6.84, ranking 92 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 48.61 and the support level at 44.52, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
46.798
Sell
MA10
46.647
Sell
MA20
47.353
Sell
MA50
48.335
Sell
MA100
48.667
Sell
MA200
49.299
Sell
Institutional Confidence
Currency: USD Updated: 2026-01-29The current institutional shareholding score of Sanofi SA is 3.00, ranking 94 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.87%, representing a quarter-over-quarter decrease of 4.36%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 68.93M shares, representing 2.83% of shares outstanding, with 2.26% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Managed Account Advisors LLC
Invesco Advisers, Inc.
Wellington Management Company, LLP
Putnam Investment Management, L.L.C.
Boston Partners
Mondrian Investment Partners Ltd.
1
2
Risk Assessment
Currency: USD Updated: 2026-01-29The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sanofi SA is 9.65, ranking 7 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.43
VaR
+2.19%
240-Day Maximum Drawdown
+24.15%
240-Day Volatility
+27.41%
Return
Best Daily Return
60 days
+2.30%
120 days
+5.42%
5 years
+8.06%
Worst Daily Return
60 days
-3.62%
120 days
-9.14%
5 years
-19.13%
Sharpe Ratio
60 days
-1.86
120 days
+0.13
5 years
+0.20
Risk Assessment
Maximum Drawdown
240 days
+24.15%
3 years
+24.57%
5 years
+34.88%
Return-to-Drawdown Ratio
240 days
-0.60
3 years
-0.05
5 years
-0.06
Skewness
240 days
-0.86
3 years
-2.40
5 years
-1.64
Volatility
Realised Volatility
240 days
+27.41%
5 years
+25.57%
Standardised True Range
240 days
+2.18%
5 years
+1.93%
Downside Risk-Adjusted Return
120 days
+16.79%
240 days
+16.79%
Maximum Daily Upside Volatility
60 days
+17.38%
Maximum Daily Downside Volatility
60 days
+18.96%
Liquidity
Average Turnover Rate
60 days
+0.18%
120 days
+0.20%
5 years
--
Turnover Deviation
20 days
+6.70%
60 days
+2.42%
120 days
+15.16%
Peer Comparison
Pharmaceuticals
Sanofi SA
SNY
7.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.89 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.77 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
